Efficacy of roxadustat for anaemia in kidney transplant recipients and its drug–drug interaction with tacrolimus: A retrospective cohort study
British Journal of Clinical Pharmacology · 30.07.2026
DOI: 10.1002/bcp.70713 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 30.07.2026. Verfasst von Haoran Qin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Third Affiliated Hospital of Soochow University, Changzhou, China. Die Arbeit nennt 51 Literaturangaben. Gefördert von: Top Talent of Changzhou 'The 14th Five-Year Plan' High-Level Health Talents Training Project, Jiangsu Pharmaceutical Association via Pharmaceutical Research Project, Hospital Pharmacy Research Project under the grant Aosaikang.
Abstract (Originalsprache)
Introduction
Post‐transplant anaemia is common in kidney transplant recipients (KTRs). Roxadustat is a novel renal anaemia therapy, but its efficacy, safety and interaction with tacrolimus (TAC) in KTRs require further investigation.
Methods
We conducted a retrospective single‐centre cohort study of 145 KTRs with post‐transplant anaemia (PTA) (March 2021 to March 2025), stratified by treatment into recombinant human erythropoietin (rhEPO, n = 73) and roxadustat (ROX, n = 72) groups. Endpoints included haemoglobin (Hb) changes, treatment response rates, liver and kidney function markers and TAC pharmacokinetics (trough concentration [C 0 ], dose [D] and C 0 /D ratio) at 1, 3 and 6 months.
Results
For both groups, at all follow‐up points, Hb levels increased significantly from baseline (all P < .05). At 6 months, compared to the rhEPO group, the ROX group showed a significantly higher treatment response rate (∆Hb > 10 g/L: 94.44% vs . 78.08%, P = 0.004) and greater Hb > 120 g/L achievement (80.56% vs . 65.75%, P = .044). No liver/kidney adverse effects were observed in either group. TAC exposure was unchanged in the rhEPO group, while in the ROX group, the C 0 increased significantly at 1 and 3 months ( P < .05), and C 0 /D was prominently higher than baseline at 1, 3 and 6 months ( P < .01).
Conclusion
Roxadustat is an effective oral treatment for PTA, demonstrating superior efficacy to rhEPO at 6 months. However, it is associated with a significant drug–drug interaction that may increase TAC exposure. These findings warrant further prospective studies to validate this drug–drug interaction.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, The Third Affiliated Hospital of Soochow University, Changzhou, China.
- Department of Pharmacy, The First People's Hospital of Changzhou, Changzhou, China.
ORCID-Profile: Nan Hu
Förderung
- Top Talent of Changzhou 'The 14th Five-Year Plan' High-Level Health Talents Training Project
- Jiangsu Pharmaceutical Association via Pharmaceutical Research Project
- Hospital Pharmacy Research Project under the grant Aosaikang
- Changzhou Science and Technology Bureau
- Changzhou Municipal Science and Technology Bureau
Zitieren
APA
Qin, H., Qian, Q., Xu, J., Xu, Y., Wang, L., & Hu, N. (2026). Efficacy of roxadustat for anaemia in kidney transplant recipients and its drug–drug interaction with tacrolimus: A retrospective cohort study. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70713
Vancouver
Qin H, Qian Q, Xu J, Xu Y, Wang L, Hu N. Efficacy of roxadustat for anaemia in kidney transplant recipients and its drug–drug interaction with tacrolimus: A retrospective cohort study. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70713
BibTeX
@article{Qin2026,
author = {Qin, Haoran and Qian, Qing and Xu, Jiahao and Xu, Yi and Wang, Liying and Hu, Nan},
title = {Efficacy of roxadustat for anaemia in kidney transplant recipients and its drug–drug interaction with tacrolimus: A retrospective cohort study},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/bcp.70713}
}
EUVIMED